[go: up one dir, main page]

PE20030336A1 - Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad - Google Patents

Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Info

Publication number
PE20030336A1
PE20030336A1 PE2002000807A PE2002000807A PE20030336A1 PE 20030336 A1 PE20030336 A1 PE 20030336A1 PE 2002000807 A PE2002000807 A PE 2002000807A PE 2002000807 A PE2002000807 A PE 2002000807A PE 20030336 A1 PE20030336 A1 PE 20030336A1
Authority
PE
Peru
Prior art keywords
indan
ona
alkyl
chloro
obesity
Prior art date
Application number
PE2002000807A
Other languages
English (en)
Inventor
Gerhard Jaehne
Volker Krone
Matthias Gossel
Martin Bickel
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20030336A1 publication Critical patent/PE20030336A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2264Obesity-gene products, e.g. leptin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A UTILIZACION DE COMPUESTOS INDAN-1-ONA SUSTITUIDOS EN C2 DE FORMULA I DONDE R1, R2, R3, R4 SON H, F, Cl, Br, I, CN, N3, NO2, OH, O-ALQUILO C1-C8, O-CICLOALQUILO C3-C8, O-CH2-FENILO, O-FENILO, O-CO-ALQUILO C1-C8, ENTRE OTROS; X ES S, SO, SO2, Y ES (CH2)p; p ES 0-3; R5 ES CF3, ALQUILO C1-C18, CICLOALQUILO C3-C8, (CH2)rCOR6, CH2-CH(NHR7)-COR8, FENILO, ; r ES 1-6; R6 ES OH, O-ALQUILO C1-C6, NH2, CH2-CH(NHR7)-COR8; R7 ES H, CO-ALQUILO C1-C4, COO-ALQUILO C1-C4; R8 ES OH, O-ALQUILO C1-C6, NH2 PARA LA PREPARACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE OBESIDAD. SON COMPUESTOS PREFERIDOS 5-CLORO-2-METILSULFANIL-INDAN-1-ONA; 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA; 5-CLORO-2-FENILSULFANIL-INDAN-1-ONA, 2-BENCENOSULFONIL-5-CLORO-INDAN-1-ONA, 5-CLORO-2-METANOSULFONIL-INDAN-1-ONA. TAMBIEN SE REFIERE AL USO CON CATINA, FENILPROPANOLAMINA, AMFEPRAMONA, MEFENOREX, EFEDRINA, LEPTINA, DEXANFETAMINA, ANFETAMINA, ENTRE OTROS
PE2002000807A 2001-08-31 2002-08-22 Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad PE20030336A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10142668A DE10142668A1 (de) 2001-08-31 2001-08-31 Verwendung von C2-substituierten Indan-1-on-Systemen zur Herstellung von Medikamenten zur Prophylaxe oder Behandlung von Obesitas

Publications (1)

Publication Number Publication Date
PE20030336A1 true PE20030336A1 (es) 2003-05-19

Family

ID=7697238

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000807A PE20030336A1 (es) 2001-08-31 2002-08-22 Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad

Country Status (10)

Country Link
US (1) US6946492B2 (es)
EP (1) EP1424999A1 (es)
JP (1) JP4342306B2 (es)
AU (1) AU2002336985B2 (es)
CA (1) CA2458555A1 (es)
DE (1) DE10142668A1 (es)
IL (2) IL160607A0 (es)
MX (1) MXPA04001853A (es)
PE (1) PE20030336A1 (es)
WO (1) WO2003020256A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010085811A2 (en) * 2009-01-26 2010-07-29 Taipei Medical University Use of pterosin compounds for treating diabetes and obesity
CN103333144B (zh) * 2013-06-17 2014-12-10 温州大学 一种2-硫基-3-卤代苯并呋喃化合物及其合成方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0009554B1 (de) * 1978-07-27 1983-04-27 Schering Aktiengesellschaft Indanyl-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
RU2073673C1 (ru) * 1987-10-19 1997-02-20 Пфайзер Инк. Рацемические и оптические активные производные тетралина и 7-гидрокситетралина
ATE246668T1 (de) * 1995-12-06 2003-08-15 Venantius Ltd Dimere indan verbindungen und ihre pharmazeutische verwendung
JP3071832B2 (ja) 1996-01-17 2000-07-31 ノボ ノルディスク アクティーゼルスカブ 縮合した1,2,4−チアジアジン及び縮合した1,4−チアジン誘導体、これらの製造および使用
PL192359B1 (pl) 1996-08-30 2006-10-31 Novo Nordisk As Pochodna GLP-1(7-37) lub analogu GLP-1(7-37), środek farmaceutyczny oraz zastosowanie pochodnej GLP-1(7-37) lub analogu GLP-1(7-37)
CN1190434C (zh) 1996-12-31 2005-02-23 雷迪实验室有限公司 新的杂环化合物、其制备方法和含有它们的药物组合物及其在治疗糖尿病和相关疾病中的应用
IL133604A0 (en) 1997-07-16 2001-04-30 Novo Nordisk As Fused 1, 2, 4-thiadiazine derivatives, their preparation and use
KR20010103786A (ko) * 1999-03-01 2001-11-23 데이비드 존 우드 갑상선 수용체 리간드로서의 옥삼산 및 유도체
FR2796070B1 (fr) * 1999-07-06 2003-02-21 Lipha Derives de benzodiazepines utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procedes de preparation
EP1078632A1 (en) 1999-08-16 2001-02-28 Sanofi-Synthelabo Use of monoamine oxydase inhibitors for the manufacture of drugs intended for the treatment of obesity

Also Published As

Publication number Publication date
WO2003020256A1 (de) 2003-03-13
EP1424999A1 (de) 2004-06-09
IL160607A (en) 2011-03-31
JP2005503396A (ja) 2005-02-03
CA2458555A1 (en) 2003-03-13
AU2002336985B2 (en) 2006-11-16
MXPA04001853A (es) 2004-06-15
IL160607A0 (en) 2004-07-25
US20030134882A1 (en) 2003-07-17
DE10142668A1 (de) 2003-03-20
JP4342306B2 (ja) 2009-10-14
US6946492B2 (en) 2005-09-20

Similar Documents

Publication Publication Date Title
PE20021091A1 (es) Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion
RU2370485C2 (ru) Амидоацетонитрильные производные
DE602005003960D1 (en) Oximesther-fotoinitiatoren
AR038723A1 (es) Cumarinas utiles como biomarcadores
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
PE20050476A1 (es) Compuestos de pirrol y pirazol
AR039789A1 (es) Pirazolopiridinas sustituidas con carbamato
BRPI0606318B8 (pt) composto, composição, e, uso de um composto
CY1113578T1 (el) 2,3-διυδρο-6-νιτροϊμιδαζο 2,1 -b-οξαζολια
AR039868A1 (es) Inhibidores selectivos de la enzima kalikreina plasmatica
PE20071328A1 (es) Compuestos de heteroarilo biciclico que contienen nitrogeno y metodos de uso
WO2003016291A1 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR δ
BR0311693A (pt) Sal de formato de o-desmetil-venlafaxina
DE60230546D1 (de) Quaternäre ammoniumverbindungen und deren verwendung als antimuscarinische wirkstoffe
ES2130079A1 (es) Resolucion de aminas
MX9302169A (es) Fenoxialquilisoxazolas de 1,2,4-oxadiazolilo y su uso como agentes antivirales.
PA8575601A1 (es) Procedimiento para su preparacion, medicamentos que comprenden estos compuestos y su uso
CO5140075A1 (es) Agentes terapeuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas
JP2004535412A5 (es)
DE60312136D1 (de) Radiofluorierungsverfahren
CO5700735A2 (es) Proceso para la preparacion de 2-cianopirrolidinas n-sustituidas
PE20030336A1 (es) Utilizacion de sistemas de indan-1-ona sustituidos en c2 para la preparacion de medicamentos para la profilaxia o el tratamiento de la obesidad
ITMI20022394A1 (it) Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
RU2009138470A (ru) Композиция для наружного применения на коже
AR035481A1 (es) Compuestos de benzosultamoxazolidinona, una composicion farmaceutica, y el uso de dichos compuestos para la manufactura de medicamentos antibacterianos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal